MELBOURNE, Oct 13 (Reuters) - Australia's CSL Ltd, the world's top plasma products group, said on Monday the U.S. Federal Trade Commission had asked it for more information on its proposed $3.1 billion takeover of smaller U.S. rival Talecris Biotherapeutics.
